March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Changes In Sub-retinal Thickening On OCT Following Ranibizumab Therapy For Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Ramu Muniraju
    Ophthalmology, King's College Hospital, London, United Kingdom
  • Raeba Mathew
    Ophthalmology, King's College Hospital, London, United Kingdom
  • Sharon Lingzhi Heng
    Ophthalmology, King's College Hospital, London, United Kingdom
  • Roxanne Crosby-nwaobi
    Ophthalmology, King's College Hospital, London, United Kingdom
  • Sobha Sivaprasad
    Ophthalmology, King's College Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  Ramu Muniraju, None; Raeba Mathew, None; Sharon Lingzhi Heng, None; Roxanne Crosby-nwaobi, None; Sobha Sivaprasad, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2921. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ramu Muniraju, Raeba Mathew, Sharon Lingzhi Heng, Roxanne Crosby-nwaobi, Sobha Sivaprasad; Changes In Sub-retinal Thickening On OCT Following Ranibizumab Therapy For Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2921.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Subretinal thickening in the foveal region on optical coherent tomography is often regarded as a poor visual prognostic indicator. In this study, we evaluated the changes in subretinal thickening over 12 months in patients on ranibizumab therapy for neovascular age related macular degeneration (nAMD) and its relation to the visual acuity and number of injections at 12 months.

Methods: : Retrospective analysis of Spectralis OCT of 51 eyes of 51 patients undergoing ranibizumab treatment for nAMD were done. The data on clinic based visual acuity at baseline and 12 months and the total number of injections were recorded. The scan protocol used was Spectralis SD-OCT 20 x 20 volume cube with 60 scans at a spatial separation of 100µm. The subretinal thickening (SRT) was defined as a homogenous layer of hyper-reflectivity of band below the external limiting membrane (ELM) extending to the band that represents the retinal pigment epithelium. The height and chord length of the SRT was measured manually using the electronic callipers. The presence or absence of external limiting membrane (ELM) at the foveal dip was also was noted. Patients with any intraretinal or subretinal fluid in the subfoveal area that interfered with the measurements were excluded.

Results: : The mean length of the SRT increased by 12 months but the height did not. The mean change of visual acuity at 12 months was 7.33 (SD 9.65). Both the length and the height of SRT did not influence the final visual outcome. The mean number of injections given over the period is 5.33 (SD 2.02). The thickness or the length of SRD did not correlate with the number of injections. However, eyes with no subfoveal ELM required significantly more injections (p=0.04). Final visual acuity did not correlate to the number of injections given.

Conclusions: : SRT does not influence final visual outcome. Eyes with preservation of ELM required less number of injections.

Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×